Business Micro

business

IndiGo Q4 FY26: Earnings reverse sharply despite stable revenue base

May 29, 2026 Neel Achary 0 Comment

May 29: InterGlobe Aviation Ltd. (“IndiGo”) today reported its fourth quarter and fiscal year 2026 results.

For the quarter ended March 31, 2026, compared to the same period last year (on a consolidated basis)

· Capacity increased by 3.4% to 43.6 billion ASKs, despite disruptions arising from the ongoing conflict in the Middle East.

· Passengers declined marginally by 1.1% to 31.6 million.

· Yield decreased by 2.2% to INR 5.20 and load factor decreased by 1.7pts to 85.8%

· Revenue from Operations increased by 1.3% to INR 224,384 million

· Fuel CASK reduced by 4.8% to INR 1.53

· CASK ex fuel ex fx increased by 7.3% to INR 3.15

· EBITDAR excluding forex impact of INR 64,354 million (28.7% EBITDAR margin), compared to EBITDAR excluding forex impact of INR 68,618 million (31.0% EBITDAR margin)

· EBITDAR of INR 22,278 million (9.9% EBITDAR margin), compared to EBITDAR of INR 69,482 million (31.4% EBITDAR margin)

· Net profit excluding impact of exceptional items and forex amounted to INR 19,206 million compared to net profit excluding impact of exceptional items and forex of INR 29,811 million

· Net loss of INR 25,369 million, compared to net profit of INR 30,675 million

For the year ended March 31, 2026, compared to year ended March 31, 2025 (on a consolidated basis)

· Capacity increased by 9.5% to 172.4 billion

· Passengers increased by 4.0% to 123.4 million against a seat growth of 5.2%

· Yield decreased by 1.7% to INR 5.06 and load factor decreased by 1.6pts to 84.4%

· Revenue from Operations increased by 5.1% to INR 849,619 million

· Fuel CASK reduced by 11.5% to INR 1.47

· CASK ex fuel ex fx increased by 3.8% to INR 3.00.

· EBITDAR excluding forex impact of INR 231,889 million (27.3% EBITDAR margin), compared to EBITDAR excluding forex impact of INR 228,612 million (28.3% EBITDAR margin)

· EBITDAR of INR 150,892 million (17.8% EBITDAR margin), compared to EBITDAR of INR 212,520 million (26.3% EBITDAR margin)

· Net profit excluding impact of exceptional items and forex amounted to INR 75,025 million compared to net profit excluding impact of exceptional items and forex of INR 88,676 million

· Net loss of INR 23,936 million, compared to net profit of INR 72,584 million

· Basic earnings per share of negative INR 61.88

Profitability Metrics

Particulars (INR mn)	Quarter ended
Particulars (INR mn)	Mar’26	Mar’25	Change
EBITDAR	22,278	69,482	-67.9%
EBITDAR excluding foreign exchange*	64,354	68,618	–6.2%
PBT	(23,517)	31,694	-174.2%
PAT	(25,369)	30,675	-182.7%
Profit excluding foreign exchange*	16,707	29,811	-44.0%
Profit excluding foreign exchange and exceptional items	19,206	29,811	-35.6%

* Net of gain on forex hedging INR 6,153 million and loss of INR 502 million for quarter ended Mar’26 and Mar’25 respectively

Particulars (INR mn)	Full year
Particulars (INR mn)	Mar’26	Mar’25	Change
EBITDAR	150,892	212,520	-29.0%
EBITDAR excluding foreign exchange*	231,889	228,612	+1.4%
PBT	(19,605)	75,934	-125.8%
PAT	(23,936)	72,584	-133.0%
Profit excluding foreign exchange*	57,061	88,676	-35.7%
Profit excluding foreign exchange and exceptional items	75,025	88,676	-15.4%

* Net of gain on forex hedging INR 8,760 million and INR 87 million for year ended Mar’26 and Mar’25 respectively

Operational Metrics*

Particulars	Quarter ended
Particulars	Mar’26	Mar’25	Change
ASK (billion)	43.6	42.1	+3.4%
RPK (billion)	37.4	36.8	+1.5%
Load Factor	85.8%	87.4%	-1.7 pts
Passengers (million)	31.6	31.9	–1.1%

*Include non-scheduled operations

Particulars	Full year
Particulars	Mar’26	Mar’25	Change
ASK (billion)	172.4	157.5	+9.5%
RPK (billion)	145.5	135.4	+7.5%
Load Factor	84.4%	86.0%	-1.6 pts
Passengers (million)	123.4	118.6	+4.0%

*Include non-scheduled operations

Mr. Rahul Bhatia, MD, said, “FY26 was marked by an exceptionally challenging operating environment, which materially impacted our profitability. Despite these conditions, the underlying performance of the business remained resilient.

During the year, our capacity grew by 9.5% and total income increased by over 6%. Excluding the impact of foreign exchange and exceptional items, IndiGo delivered a profit of INR 75 billion.

We continue to maintain a strong balance sheet with substantial liquidity, demonstrating resilience through prolonged periods of volatility. I would like to thank our 123 million customers for placing their trust in us, and our 69,000 dedicated IndiGo team members for their extraordinary professionalism. While the near term remains volatile, we remain firmly focused on disciplined execution, cost efficiency, and long-term value creation.”

Revenue and Cost Comparisons

Total income for the quarter ended March 2026 was INR 238,307 million, an increase of 3.2% over the same period last year. For the quarter, our passenger ticket revenues were INR 194,258 million, a decrease of 0.7% and ancillary revenues were INR 23,515 million, an increase of 9.2% compared to the same period last year.

Particulars (INR mn)	Quarter ended
Particulars (INR mn)	Mar’26	Mar’25	Change
Revenue from operations	224,384	221,519	+1.3%
Other income	13,923	9,456	+47.2%
Total income	238,307	230,975	+3.2%
RASK* (INR)	5.30	5.26	+0.8%
Yield (INR/Km)	5.20	5.32	–2.2%

*Net of finance income of INR 7,374 million and INR 9,509 million for quarter ended Mar’26 and Mar’25 respectively

business

India’s Homegrown Pet Wellness Brand Dogsee Chew Makes a Historic Cannes 2026 Debut, Turning the Spotlight on Global Pet Wellness

May 29, 2026 admin 0 Comment

Business Wire India

India’s leading natural pet wellness brand, Dogsee Chew, made a landmark debut at the 79th edition of the Cannes Film Festival on May 16, 2026, becoming one of the first Indian pet wellness brands to represent the industry on one of the world’s most prestigious global platforms.

Representing the brand at Cannes were co-founders and pet parents Sneh Sharma and Bhupendra Khanal, whose powerful red carpet appearance highlighted the growing cultural and global significance of pet wellness. As pets increasingly become integral members of families worldwide, conversations around natural nutrition, preventive care, wellness, and mindful pet parenting are rapidly entering mainstream lifestyle and consumer spaces.

Founded in 2015, Dogsee Chew pioneered the Himalayan yak chew category globally with its natural Chhurpi-based dog treats sourced from the Himalayas. Today, the Bengaluru-based company is present in over 30 countries and trusted by more than a million pet parents worldwide for its preservative-free, rawhide-free, and natural pet nutrition offerings.

What made the Cannes appearance especially emotional was the founders’ heartfelt tribute to their late dog, Mowgli — the inspiration behind Dogsee Chew’s journey. The theme of their red carpet appearance, titled “An Ode To Mowgli,” beautifully blended emotion, fashion, and Himalayan heritage.

Sneh Sharma wore a custom ensemble by Indian label Duchess Kumari, paired with jewellery from Kushal Fashion Jewellery. Her outfit featured intricate Himalayan-inspired detailing along the hem symbolising the brand’s roots, while the corset carried an embroidered motif of Mowgli. Bhupendra Khanal wore a custom suit by Twamev featuring Mowgli’s embroidered motif on the left chest — a subtle yet deeply emotional tribute to the dog who inspired the company’s vision.

Speaking about the moment, Sneh Sharma, Co-founder, Dogsee Chew, said, “Walking the Cannes red carpet was an incredibly emotional and proud moment for us. Mowgli was not just our pet, but the soul behind Dogsee’s journey. Through this tribute, we wanted to celebrate the unconditional love pets bring into our lives while also representing India, the Himalayas, and the growing global conversation around pet wellness on such an iconic platform.”

Bhupendra Khanal, Co-founder, Dogsee Chew, added, “For us, Cannes is much bigger than a red carpet moment. It represents how far the pet wellness industry has evolved globally. Seeing a Himalayan-born Indian brand being recognised on an international stage reinforces the growing importance of conscious pet parenting, natural nutrition, and wellness-led lifestyles worldwide. Carrying Mowgli’s memory with us made this moment deeply personal and unforgettable.”

Dogsee Chew’s presence at Cannes also reflects the larger transformation taking place within the global pet care industry. Once considered a niche segment, pet wellness has rapidly emerged as one of the world’s fastest-growing consumer categories, driven by increasing awareness around animal health, preventive care, and premium nutrition.

Over the years, Dogsee Chew has expanded its portfolio beyond Himalayan Yak Chews into dental chews, training treats, puffed snacks, functional variants, and wellness supplements under its Dogsee Activet Plus+ range. As the company continues to strengthen its presence across India, the US, Canada, Europe, and the Asia-Pacific region, Dogsee Chew aims to position Himalayan natural nutrition as a global benchmark in pet wellness while building one of the world’s most trusted pet care brands from India.

YouTube Link: https://www.youtube.com/shorts/H7C0FbMm7P0

business

Large Format Marble: Why Bigger Blocks Are Changing the Way We Design Spaces

May 29, 2026 Neel Achary 0 Comment

Kishangarh :In contemporary architecture and interior design, scale is no longer defined only by square footage. It is shaped by how uninterrupted a space feels. Clean sightlines, continuous surfaces, and material consistency are becoming central to how luxury is expressed today. Within this shift, large format marble has emerged as a defining element.

What begins at the quarry, with the selection of larger marble blocks, directly influences how a space is ultimately experienced. Bigger blocks allow for larger cuts, fewer joints, and a level of visual continuity that smaller formats struggle to achieve.

From Block to Scale

The journey of large format marble starts long before installation. It begins with sourcing blocks that are not only sizable but also structurally consistent.

Larger blocks provide the opportunity to extract bigger pieces with minimal variation. This becomes critical when designing expansive floors or full-height wall cladding where continuity is essential.

For architects, the ability to work from a single block or a set of closely matched blocks allows for greater control over the final outcome. It reduces unpredictability and ensures that the material reads as one cohesive surface rather than a collection of parts.

Fewer Joints, Greater Continuity

One of the most immediate advantages of large format marble is the reduction of joints.

In traditional applications, smaller pieces create visible interruptions across a surface. While these can be managed through careful layout, they still segment the space visually.

Large format applications minimize these interruptions. Floors appear more expansive. Walls feel uninterrupted. The eye moves seamlessly across the surface without distraction.

This continuity has a direct impact on how space is perceived. Even compact areas can feel larger when visual breaks are reduced.

Designing for Modern Lifestyles

As living spaces evolve, there is a growing preference for open plans and fluid transitions between areas. Materials are expected to support this flow rather than interrupt it.

Large format marble aligns naturally with this approach. It allows designers to extend the same material across multiple zones, creating a sense of cohesion throughout the home.

Whether it is a living area that flows into a dining space, or a bedroom that extends into a walk-in area, the use of larger pieces helps maintain visual harmony.

Precision at the Planning Stage

Working with large format marble requires a higher degree of planning. Every cut, every placement, and every joint must be considered in advance.

This level of precision begins at the block selection stage. Understanding how the marble will open up, how the veining will align, and how different pieces will come together is essential.

It is a process that combines technical knowledge with design intent. When executed well, the result is a space where the material feels intentional rather than applied.

Elevating Material Presence

Larger surfaces allow the natural character of marble to be appreciated more fully.

Veining becomes more legible. Patterns can flow uninterrupted. The material is experienced in its entirety rather than in fragments.

This elevates marble from being a surface finish to becoming an integral part of the architectural language. It defines the space rather than simply covering it.

A Shift Towards Material Clarity

There is a noticeable movement in design towards clarity and restraint. Materials are being chosen not for how much they can show, but for how well they can support a space over time.

Large format marble fits within this shift. Its strength lies in its ability to simplify. To reduce visual noise. To create environments that feel calm and resolved.

Mr. Praveen Gangwal, founder of Tilak Marbles, notes, “When you work with larger blocks, you are not just increasing size, you are increasing possibility. The continuity you achieve in the final space depends entirely on what you begin with. Large format marble allows architects to think beyond pieces and start designing in surfaces.”

Looking Ahead

As expectations around design continue to evolve, the demand for materials that offer both scale and consistency will only grow.

Large format marble represents more than a technical advancement. It reflects a broader shift in how spaces are conceived. From segmented layouts to seamless environments. From decorative surfaces to material-led design.

What begins as a larger block at the source ultimately transforms into a more expansive experience within the space.

And in that transition lies the future of how marble will be used, not in parts, but as a continuous expression of design.

business

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

May 29, 2026 admin 0 Comment

Business Wire India

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy

BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL

Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA^® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI^™(sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL.

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:
“CLL is a disease patients live with for years, and the real measure of a therapy is how it performs over the long arc of treatment. Our data at ASCO show that BRUKINSA continues to deliver sustained disease control, which can give physicians and patients confidence to stay the course. Additionally, robust, real-world analyses reinforce its role as a best-in-class BTK inhibitor, with data favoring BRUKINSA over other BTK inhibitors across several efficacy and safety endpoints. With BRUKINSA as the foundation, we are building a broad, differentiated hematology franchise designed to push the field further, including our ZS combination, which achieved deep responses and unprecedented rates of uMRD, and emerging approaches like our BTK degrader, tacabrutideg. Together, these foundational therapies reflect our commitment to redefining what patients should expect from therapy both today and in the future.”

78-month SEQUOIA data highlight the long-term impact of first-line treatment choice in CLL (Poster Presentation: 544; June 1, 2026, 9:00 AM-12:00 PM CDT)
SEQUOIA now provides the longest reported follow-up for a next-generation BTK inhibitor in first-line CLL, enabling a deeper understanding of how treatment outcomes evolve over time. After a median follow-up of 84.01 months (range, 0.0-101.5), BRUKINSA continued to show benefit over bendamustine-rituximab (BR) in patients with treatment-naive CLL/SLL, with progression-free survival (PFS) outcomes that are unprecedented among BTK inhibitors. Key highlights include:

78-month PFS: 71.8% (95% CI, 65.3-77.3) for BRUKINSA vs. 31.0% (95% CI, 24.3-37.9) for BR
78-month COVID-adjusted PFS: 74.6% (95% CI, 68.1-79.9) for BRUKINSA vs. 31.4% (95% CI, 24.7-38.4) for BR
- PFS for patients with unmutated IGHV: 70.4% (95% CI, 61.0-77.9) for BRUKINSA vs. 17.4% (95% CI, 9.6-27.1) for BR
- PFS for patients with mutated IGHV: 81.8% (95% CI: 72.2-88.4) for BRUKINSA and 45.1% (95% CI: 34.4-55.2) for BR
78-month PFS2: 81.3% (95% CI, 75.6-85.8) for BRUKINSA vs. 74.4% (95% CI, 67.8-79.8) for BR
78-month COVID-adjusted PFS2: 84.7% (95% CI, 79.2-88.8) for BRUKINSA and 76.4% (95% CI, 69.9-81.7) for BR
- Of the BRUKINSA-treated patients who progressed (26/241), half received subsequent therapy with BCL2 inhibitor-based salvage therapy and 69.2% had not progressed after more than 3 years of follow-up.
Time to next treatment (TTNT) favored BRUKINSA over BR (HR, 0.24; 95% CI, 0.16-0.35; P<.0001)
Safety: consistent with the results of prior BRUKINSA studies with no new safety signals.

PFS2 captures outcomes beyond first disease progression, measuring time to disease progression on subsequent therapy or death. In CLL, this endpoint provides important insight into how first-line treatment impacts long-term disease control across multiple lines of therapy.

Constantine Tam, M.B.B.S., M.D., Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University, said:
“In an indolent disease like CLL, many patients value maintaining disease control over the course of their life, not just in the first year or two of treatment. The continued long-term follow-up from SEQUOIA shows that zanubrutinib can deliver sustained disease control. This is the kind of evidence that allows clinicians and patients to make first-line decisions with real confidence about what lies ahead.”

Real-world efficacy and safety data consistently underscore foundational BRUKINSA as the best-in-class BTKi for TN CLL (Poster Presentations: 545, 543 and 540; June 1, 2026, 9:00 AM-12:00 PM CDT)
In addition to the update from SEQUOIA, BeOne will present data from new analyses of large and robust datasets, which demonstrate consistent and significant real-world benefits of using BRUKINSA over other BTK inhibitors. Key highlights include:

In a real-world analysis of 10,523 Medicare patients, who were diagnosed with CLL/SLL and received frontline treatment with a BTK inhibitor, patients treated with BRUKINSA had a statistically significantly lower risk of death, advancing to next line, or discontinuing treatment, than those on ibrutinib or acalabrutinib. Similar results were observed across age subgroups. (Poster Presentation: 545)
In a separate real-world analysis of Komodo database claims from 16,788 patients with treatment-naïve CLL, BRUKINSA had a longer TTNT (unadjusted HR, 0.88; 95% CI, 0.79-0.97; P=.009) and overall survival (OS; HR, 0.72; 95% CI, 0.62-0.82; P<.001). (Poster Presentation: 543)
A retrospective analysis of 233,362 newly diagnosed CLL patients who initiated treatment with a BTK inhibitor, the atrial fibrillation rate within 1 year was lowest for BRUKINSA at 11% and 13% for acalabrutinib and 16% for ibrutinib (overall P<.0001). (Poster Presentation: 540)

Deep, rapid responses with BRUKINSA plus sonrotoclax (ZS) point to the future of time-limited treatment in CLL, including high-risk disease (Poster Presentation: 541; June 1, 2026, 9:00 AM-12:00 PM CDT)
In the Phase 1/1b study in patients with treatment-naïve CLL/SLL (median follow-up of ~34 months), the all-oral combination of BRUKINSA and next-generation BCL2 inhibitor sonrotoclax (ZS) demonstrated unprecedented rates and kinetics of undetectable minimal residual disease (uMRD), including in patients with high-risk cytogenetics. Key highlights include:

Overall response rate (ORR): 100%, with complete responses in 59.5% of patients
Best uMRD4 rate 98.8%
- No patient that achieved uMRD4 reverted to uMRD positivity.
Best uMRD in patients with TP53 mutation/del(17p): 92.9% across 2 dose levels
Median time from combination start to uMRD4: 4.5 months
No disease progression events observed at the recommended Phase 2 dose of 320mg, including patients who electively discontinued therapy
Safety: consistent with previously reported BRUKINSA and sonrotoclax combination studies.

These data will also be presented as encore presentations at the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm) along with more than 30 other data sets from BeOne.

About BRUKINSA^® (zanubrutinib)
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

With the broadest label globally, BRUKINSA is the foundational BTK inhibitor and is the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing.

The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.

About BEQALZI^™ (sonrotoclax)
BEQALZI^™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. Sonrotoclax has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,500 patients have been enrolled across the broad sonrotoclax global development program.

BEQALZI is approved by the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a BTK inhibitor. It is also approved in China for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy, including a BTK inhibitor.

About Tacabrutideg (BGB-16673)
Tacabrutideg is a foundational and potential first-in-class and best-in-class orally available Bruton’s tyrosine kinase (BTK) degrader. With 1,200+ patients dosed to date in an extensive global clinical development program, tacabrutideg is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, tacabrutideg is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.

The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to tacabrutideg for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted tacabrutideg PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

Select Important Safety Information for BRUKINSA
Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).

In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

Please see full U.S. Prescribing Information including U.S. Patient Information.

Select Important Safety Information for BEQALZI^™ (sonrotoclax)
Serious and sometimes fatal adverse reactions have occurred with BEQALZI, including tumor lysis syndrome (TLS), serious infections, neutropenia, and embryo-fetal toxicity. BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome.

In the safety population (N=115), tumor lysis syndrome occurred in 7% of patients who followed the recommended dose ramp-up. Serious infections occurred in 14% of patients, and Grade 3 or 4 infections occurred in 17% (fatal: 2.6%), with pneumonia (10%) being the most common Grade 3 or greater infection. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%), and febrile neutropenia occurred in 1.7% of all patients. The most common adverse reactions (≥15%) were pneumonia (16%) and fatigue (16%). The most common Grade 3–4 laboratory abnormalities (≥15%) were decreases in lymphocytes (29%) and neutrophils (18%).

Please see full Prescribing Information.

The information provided in this press release is intended for a global audience. Product indications vary by region.

About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential patient benefits of zanubrutinib, sonrotoclax and tacabrutideg; BeOne’s ability to redefine what patients should expect from therapy; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529392296/en/

news

FSSAI Seeks Explanation from IRCTC Over Alleged Hygiene Lapses in Train Catering Services

May 29, 2026 Neel Achary 0 Comment

New Delhi, May 29 (BNP): The Food Safety and Standards Authority of India (FSSAI) has issued a formal notice to the Indian Railway Catering and Tourism Corporation (IRCTC) over allegations of unhygienic practices in onboard catering services after a video circulating on social media allegedly showed utensils being washed inside a train toilet, raising serious concerns over passenger food safety and hygiene standards.

FSSAI Seeks Explanation from IRCTC Over Alleged Hygiene Lapses in Train Catering Services

Representational image

Taking cognisance of the incident, FSSAI sought a detailed factual explanation from IRCTC and directed the agency to submit its comments on the matter. The food safety regulator observed that, if verified, the alleged practice would amount to a serious violation of hygiene and sanitary norms prescribed under Schedule 4 of the Food Safety and Standards (Licensing and Registration of Food Businesses) Regulations, 2011.

Under the regulations, food business operators are required to maintain stringent hygiene protocols for food processing, handling, cleaning and washing to ensure that food and food-contact surfaces remain free from contamination. Officials emphasised that any lapse in compliance could pose potential health risks to passengers and undermine food safety standards in railway catering services.

FSSAI further reiterated that adherence to food safety regulations is mandatory for all catering operations, including services managed directly by IRCTC as well as those handled through contractual personnel engaged in onboard food distribution.

The incident has reignited public concern over hygiene and quality control in train catering, particularly on long-distance routes where thousands of passengers depend on onboard meals during travel. Experts and consumer groups have stressed the need for stricter monitoring, regular inspections and stronger enforcement of food safety protocols to improve accountability and ensure safe food handling practices.

IRCTC is expected to respond to the notice and clarify the circumstances surrounding the alleged incident, following which authorities may decide on appropriate corrective or regulatory measures.

The development once again underscores the importance of maintaining high hygiene standards in mass transit systems, where lapses in food safety can have wide-reaching implications for public health and passenger confidence.

news

Meghalaya Promotes Community-Led Tourism by Empowering Local Families

May 29, 2026 Neel Achary 0 Comment

Mumbai, May 29: When travellers visit a new place, they don’t always look for scenic spots. They look for genuine human connections. For years, Meghalaya has offered that warmth, rooted in its rich culture and deep hospitality. Today, that warmth is driving economic growth.

Meghalaya Promotes Community-Led Tourism by Empowering Local Families

The numbers tell this story clearly. Shillong recently topped Skyscanner’s 2025 Report as the most-searched travel destination in India. It is drawing more visitors than ever under its new tourism identity, Symphony in the Mist. Tourist arrivals have surged from roughly 12 lakhs in 2018 to over 16 lakhs today, and the State has set an ambitious target of 21 lakhs by 2028. In April 2026, NITI Aayog’s Divya Bharat: A Window to the Soul of India report added further weight to this momentum. It identified Meghalaya as one of India’s few year-round travel destinations with no clear off-season. It highlighted the State’s living root bridges, extensive cave systems, and indigenous cultural traditions. The message was clear: Meghalaya is no longer a seasonal stop. It is a destination for all seasons.

But recognition alone does not fill a room. As visitor numbers climbed, a serious challenge emerged. Demand was outpacing supply. Many high-potential destinations lacked adequate lodging, and tourist spending went unrealised. The government saw that building massive hotels was not the only answer. Instead, it chose to empower the families who call these hills home. This thinking made the homestay model the cornerstone of Meghalaya’s tourism strategy.

The government took the first step in September 2023 by launching the Meghalaya Tourism Homestay Scheme in convergence with the Prime Minister’s Employment Generation Programme (PMEGP). The scheme gives financial assistance of up to 70% for projects costing up to ₹10 lakhs. This includes a 35% subsidy under PMEGP and an equal 35% from the State’s Tourism Department, making it accessible to first-time entrepreneurs and rural households. The response was swift. The scheme sanctioned 900 applications. On the ground, more than 490 homestays became operational, creating 1,000 rooms and around 1,500 livelihood opportunities.

With this proof of success, the government moved to scale. It launched the Chief Minister’s Meghalaya Homestay Mission in September 2025, building on the earlier scheme with greater ambition. The Mission targets 3,000 new homestays and 15,000 direct and indirect jobs by 2028. The support structure improved as well. New homestays can receive a subsidy of up to 70%, capped at ₹7 lakhs. Existing homestays can claim an upgradation incentive of up to ₹2 lakhs to improve quality and visitor experience. Early momentum has been strong, with 80 applications already approved across 10 districts, showing participation from every part of the State.

These are not just statistics. For people like Daminot Kharshandi from Ri Bhoi district, a first-generation entrepreneur and scheme beneficiary, this support changed everything. “The Homestay Scheme gave me the financial confidence to launch my business, which I have successfully expanded,” he added. “The State’s Meghalaya Tourism branding policy has also brought more footfalls and revenue.” His story is becoming a familiar one across the region. It shows that the right support, reaching the right people, multiplies.

One such story belongs to Donny Esmond Rapsang. His Friendship Homestay at Umden Umsaitprah, Umroi is a story of resilience and community empowerment. Rapsang once moved between multiple small jobs and businesses to support his family. The Government of Meghalaya’s Homestay Scheme opened a new door. With financial assistance of over ₹9 lakh, he began construction in 2023, completed the homestay in 2024, and opened it to the public in 2025. Today, the homestay supports his household and has created opportunities for local youth involved in its construction and operations. His journey, like Daminot’s, shows how tourism-based initiatives can strengthen livelihoods, promote self-employment, and empower rural communities.

This wide participation reflects what Chief Minister, Shri Conrad K. Sangma has consistently emphasised. These initiatives are not isolated interventions. They build an ecosystem where homestay owners, local transport providers, food vendors, and tourist guides all grow together. The State treats smaller homestays as just as vital as large infrastructure, spreading the economic benefits of tourism to the grassroots rather than concentrating them at the top.

Nowhere is this philosophy more visible than in the State’s plans for the upcoming 39th National Games, 2027. Meghalaya intends to house visitors in homestays rather than traditional Games Villages, placing local families at the centre of a national stage.

As that moment approaches, the homestay revolution tells a bigger story about how Meghalaya is choosing to grow. By giving ordinary people, the tools to succeed, the Government of Meghalaya is doing more than expanding accommodation. It is building something more enduring, a tourism economy where benefits flow directly to the families who have always been its greatest hosts.

business

FPT and CP Partner to Advance AI-Led Agri-Food Value Chains

May 29, 2026 admin 0 Comment

Business Wire India

Charoen Pokphand Foods Public Company Limited (CPF) and FPT Corporation (FPT) recently signed a Memorandum of Understanding (MoU) for a strategic cooperation in Vietnam between CPF and FPT to advance AI-led and digital transformation in agri-food value chains, with the focus on agriculture, food processing, smart manufacturing, and supply chain management in Vietnam.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529529814/en/

The MoU exchange ceremony was witnessed by H.E. Anutin Charnvirakul, Prime Minister of the Kingdom of Thailand, and H.E. To Lam, Party General Secretary and State President of Vietnam, alongside senior government officials and business leaders from both countries.

The MoU exchange ceremony took place at the Thailand-Vietnam Business Forum 2026, held on May 28, 2026, in Bangkok. The event was attended by the Prime Minister of the Kingdom of Thailand, H.E. Anutin Charnvirakul, and the Vietnam Party General Secretary and State President, H.E. To Lam, commemorating the 50th Anniversary of Vietnam–Thailand Diplomatic Relations (1976–2026) under the theme “Growing Together,” highlighting Vietnam’s strategic commitment to technology-driven growth.

Under the agreement, C.P. Vietnam Corporation (C.P. Vietnam), a subsidiary under CPF and Vietnam’s leading integrated agri-food corporation, and FPT will explore the development and deployment of AI and digital solutions across C.P. Vietnam’s integrated Feed-Farm-Food value chain, from farm to family, and supply chain networks, from 2026 to 2028 and beyond.

The scope of cooperation covers strategic areas including Smart Camera and AI Vision, Smart Scales and Customer Experience, Smart Manufacturing and Smart Supply Chain, Industrial Internet of Things (IIoT) platforms, Centralized Data Integration, Agentic AI for Operational Intelligence, Food Safety and Traceability, and Smart Farm Model and Farmer Ecosystem Expansion.

In the pilot phase, both sides will establish Smart Farm models at selected C.P. Vietnam facilities, targeting about 20% reduction in operational costs and 100% food safety traceability. The ambition is to turn the Smart Farm model into a practical engine for wider transformation, bringing FPT’s AI solutions into more C.P. Vietnam facilities and across its contract farmer network. This can create a pathway for Smart Farm and AI AgriTech solutions to reach farmers nationwide, supporting Vietnam’s broader agricultural modernization agenda.

“With our AI-first strategy and proven capabilities in supporting global manufacturers, FPT will cooperate with C.P. to build a smarter, more connected, and resilient agri-food ecosystem, moving towards AI-enabled smart agriculture while adding value to all of its stakeholders. This partnership reflects a broader opportunity for Vietnam and Thailand to harness next-generation technologies to drive regional impact, strengthen food security, and sustain the growth and competitiveness of Southeast Asia’s agricultural value chains,” said Levi Nguyen, Chief Executive Officer of FPT Thailand and FPT Taiwan, FPT Corporation.

“C.P. Vietnam supports the Vietnam–Thailand Comprehensive Strategic Partnership Action Program 2026–2030, which promotes economic cooperation, investment, technology transfer, and digital transformation. Through this cooperation with FPT, we look forward to leveraging digital transformation across C.P. Vietnam’s integrated Feed–Farm–Food value chain, from farm to family. C.P. Vietnam continues its efforts to become a trusted partner in shaping the sustainable future of Vietnam’s agri-food industry and nurturing life by delivering safe, high-quality offerings through innovative and sustainable practices,” said Pawalit Ua-amornwanit, Chief Executive Officer of C.P. Vietnam.

Since its establishment, FPT has become a trusted technology partner for more than 500 enterprises in the Asia Pacific, helping enterprises modernize complex operations and accelerate digital transformation at scale. With Thailand among the key regional markets, the company serves leading enterprises across banking and finance, insurance, retail, automotive, manufacturing, healthcare, energy and utilities, consumer goods, and aviation, with clients and partners including Unilever, Central Group, AIA, LMG, Prudential, KBTG, SCB, KKP, TTB, FWD, Honda, Panasonic, Mitsubishi, Hitachi, Microsoft and Sunline. As a co-founder of the Vietnam–Thailand Chamber of Commerce (VietCham Thailand), the company also plays an active role in strengthening bilateral cooperation.

About FPT

FPT Corporation (FPT) is a globally leading Vietnam-headquartered technology and IT services provider, with operations spanning more than 30 countries and territories. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. With a strong focus on mastering strategic technologies, FPT continues to drive innovation across industries. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses.
For more information about FPT’s global IT services, please visit https://fptsoftware.com.

About C.P. Vietnam Corporation

C.P. Vietnam Corporation, a member of Charoen Pokphand Group, has been operating in Vietnam since 1993. Today, C.P. Vietnam is one of the leading agri-food corporations in Vietnam, operating an integrated Feed – Farm – Food business model in accordance with international standards to deliver high-quality and sustainable food solutions from farm to family.

Sustainability is embedded at the core of C.P. Vietnam’s business strategy and is driven through three key commitments: climate protection, improving quality of life, and advancing sustainable food systems. C.P. Vietnam is working toward its goal of achieving net-zero emissions by 2050, while continuing to expand renewable energy adoption and strengthen responsible resource management across its operations.

C.P. Vietnam currently operates 12 animal feed mills, 2 pork slaughterhouses, and 6 food processing plants, including one of Southeast Asia’s most advanced integrated chicken processing complex for export, alongside a nationwide network of modern farms across multiple provinces and cities.

Throughout more than three decades of operations in Vietnam, C.P. Vietnam has remained steadfast in its “Three Benefits Principle”, placing the benefits of the country and its people at the center of its values. C.P. Vietnam continuously strives to be the trusted partner in shaping the sustainable future of agri-food industry.

For more information about C.P. Vietnam, please visit https://www.cp.com.vn

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529529814/en/

business

Fintech Week London returns with new city-wide festival to match the capital’s global fintech status

May 29, 2026 Neel Achary 0 Comment

Fintech Fringe is behind the bigger, bolder format with the backing of the Department for Business and Trade and London & Partners

London, 29 May 2026: London has long earned its place as one of the world’s defining fintech centres. Dealroom’s latest report just confirmed London as the world’s number one fintech ecosystem – home to 137 unicorns and a combined enterprise value of $714 billion.

New York has a fintech week. Singapore has one too. It is time London stepped up a gear with its own fintech week to reinforce why London is the world’s best city to scale a fintech business.

Fintech Week London returns from 7 to 11 September 2026 under new leadership, backed by Fintech Fringe founder Calypso Harland and the UK’s fast-growing fintech community.

Anchored by the Scale & Grow Summit on 9 and 10 September in central London, the event is expected to attract more than 1,500 founders, investors, financial institutions, policymakers, regulators and international fintech leaders to the capital.

This year’s theme is Growth with Agency, and focuses on the practical questions now shaping fintech growth. Sessions will examine how AI is changing competitive advantage, how regulation is affecting growth strategies, how fintechs can access capital, and how the long-anticipated convergence of fintech, crypto and payments is beginning to reshape the market.

Fintech Fringe is opening the week to companies, associations, communities and event organisers across London, inviting them to host their own events as part of a shared city-wide fintech moment. The model gives the wider ecosystem, including smaller companies and emerging communities, a way to access a larger audience and contribute to the global fintech conversation.

Calypso Harland, Founder of Fintech Fringe, said:

“London needs a fintech week that reflects the ecosystem itself: ambitious, practical, international and open to the people building what comes next. Fintech Week London is a platform for the whole city – from founders and investors to banks, regulators, associations and emerging communities. We’re here to rally everyone together and show the world why London is built to create champions.”

Emma Banymandhub, CEO of The Payments Association, said:

“Calypso is a natural collaborator and the perfect person to bring the ecosystem together to bridge the divide between fintech, crypto and payments. These communities often live in parallel universes, and bringing them together can only mean better things for the industry as a whole. The Payments Association is delighted to support.”

The relaunch follows Fintech Fringe’s merger with Fintech Week London last year. Since launching in 2023, Fintech Fringe has grown rapidly, with its own festival tripling in size over three years.

Fintech Week London 2026 will run from 7 to 11 September, with the Scale & Grow Summit taking place from 9 to 10 September.

For hosting, speaking and partnership opportunities, visit www.fintechweek.london.

business

Panasonic showcases integrated display and communication technologies for a connected India

May 29, 2026 Neel Achary 0 Comment

Panasonic showcases integrated display and communication technologies for a connected India

New Delhi, May 29: Panasonic Life Solutions India, through its System Solutions Division (SSD), hosted the Panasonic Tech Summit 2026 in New Delhi on May 19 and 20, introducing new experiential zones for Education, Golf Simulation, and Healthcare as part of its expanding connected technology ecosystem. The two-day summit brought together industry experts, enterprise leaders, and business decision-makers to experience Panasonic’s integrated ecosystem of display, projection, broadcast, and connected visual communication solutions across diverse industry environments.

The summit, themed “Turning Technology into Value,” featured multiple experience-led zones including Retail, Transportation, Corporate Offices, QSR, Home Theatre, Fine Pitch Active LED Comparison, Education Zone, Security Solutions, Projection Simulation zone and Panasonic’s comprehensive Professional Display lineup. The showcase featured a wide range of technologies including Active LED Videowalls, HD PTZ cameras, 4K camcorders, SIP Video Door Phones, integrated CCTV systems, Intelligent and Interactive digital signage solutions, and immersive projection technologies powered by the Panasonic projectors, highlighting Panasonic’s focus on enabling connected, intelligent, and immersive experiences across industries.

Speaking on the occasion, Bhavya Jain, Business Chief-India & SAARC, Professional Displays, Projectors & Broadcast Solutions, Panasonic Life Solutions India Pvt. Ltd., said, “Today, businesses are looking beyond standalone products and focusing on connected technology ecosystems that can simplify operations, enhance engagement, and create more meaningful experiences. Through Panasonic Tech Summit 2026, we are demonstrating how integrated display, projection, broadcast, and communication solutions can help businesses operate more efficiently while also delivering seamless and immersive experiences for consumers across sectors such as education, healthcare, retail, transportation, Education and corporate environments. Our focus remains on building intelligent, scalable, and future-ready solutions that can support the evolving needs of both businesses and customers in an increasingly connected world.”

Experiential Zones Demonstrating Integrated Technology Ecosystems

Key showcase areas included:

QSR Hub: Showcased professional digital menu boards, high-brightness storefront displays, stretch displays, eSignCards, and Panasonic’s India-developed Digital Signage platform enabling centralized menu, pricing, and promotional management across restaurant environments.
Education Zone: Showcased Panasonic’s Smart Classroom ecosystem featuring large Active LED displays, PTZ cameras, 4K camcorders, centralized control systems, and Interactive Flat Panel display designed to enable interactive, hybrid, and connected learning experiences.
Retail Hub: Demonstrated dynamic retail communication solutions including display standees, Electronic Smart Shelf Labels, latest Lift-and-Learn technology (Intellosign), dual-side professional displays, eSignCards, and Panasonic Digital Sign Edge for centrally managed and real-time in-store communication.
Transit Hub: Simulated airport and metro environments featuring passenger information displays, dual-side displays, Active LED screens, stretch displays, e-ink wayfinding totems, Tensor Poles, and Electronic Smart Labels designed to enable seamless communication and navigation across high-movement spaces with a moto to move seamlessly with Information at hand.
Corporate Office Hub: Featured connected workplace collaboration solutions including ultra-wide displays suitable for enterprise class Video conferencing, interactive Flat panels, RoomBook, Solutions (Meeting Schedulars), broadcast cameras, eSignCards, and hybrid meeting room solutions designed to enhance communication and workplace collaboration.
Healthcare Zone: Demonstrated Panasonic’s connected healthcare ecosystem featuring ePaper displays for OPD and patient communication, bedside information cards, pharmacy shelf labels, and professional displays designed to simplify hospital operations and enhance patient experiences through centralized information management system SignEdge.
Golf Simulation Zone: Featured immersive golf simulation powered by Panasonic’s projectors, delivering realistic gameplay and training experiences with enhanced green visibility, responsive visuals, and seamless simulation software integration
Projector & Home Theatre Zone: Demonstrated Panasonic’s high-brightness projection solutions for large venues and immersive home theatre experiences, showcasing cinema-quality visuals, consistent brightness, rich contrast, and projection mapping capabilities across varied environments.
Fine Pitch Active LED Comparison Zone: Demonstrated Panasonic’s Fine Pitch Active LED portfolio across multiple pixel pitches including COB and SMD panels, enabling visitors to experience differences in clarity, detail, and viewing impact across applications and viewing distances.
Comprehensive Professional Display Lineup: Showcased Panasonic’s professional display portfolio ranging from compact to ultra-large screens, highlighting how different display formats and scales support communication across meeting rooms, retail spaces, hospitality environments, QSRS, control rooms and many more applications.
Security Solutions Zone: Featured Panasonic’s integrated security ecosystem including SIP Video Door Phones, IP, Analog and Hybrid Video Door Phone systems, along with Bullet, Dome, and PTZ CCTV cameras designed for connected and reliable monitoring across residential and commercial environments.

technology

Tesla Cybercab Drives Itself Out of GigaTexas Factory in Autonomous Breakthrough

May 29, 2026 Neel Achary 0 Comment

Austin, Texas, May 29 (BNP): In a striking demonstration of autonomous vehicle technology, Tesla’s Cybercab was seen driving itself out of the company’s Gigafactory Texas (GigaTexas), marking another milestone in the electric vehicle maker’s push toward fully autonomous transportation. Videos shared online showed multiple Cybercab units autonomously exiting the factory and navigating toward holding or staging areas without human drivers.

The development comes as Tesla accelerates production of its purpose-built autonomous vehicle, designed specifically for robotaxi operations. Unlike conventional vehicles, the Cybercab has been engineered without a steering wheel or pedals and is intended to function entirely through Tesla’s Full Self-Driving (FSD) technology. Production of the vehicle began at GigaTexas earlier this year as part of the company’s broader strategy to expand autonomous mobility solutions.

Tesla Chief Executive Officer Elon Musk recently shared footage of Cybercab units autonomously leaving the factory, describing the vehicle as “purpose-built for autonomy.” The footage has generated significant attention across the technology and automotive sectors, with supporters viewing it as a glimpse into the future of transport and critics pointing to ongoing regulatory and safety challenges surrounding fully driverless systems.

The Cybercab forms a central pillar of Tesla’s long-term robotaxi vision, though the company has acknowledged that scaling autonomous operations will be gradual and subject to safety validation and regulatory approvals. Industry observers note that while autonomous production and factory movement represent technological progress, broader public deployment of fully driverless vehicles continues to face technical, legal and infrastructure-related scrutiny.

The latest footage nevertheless signals Tesla’s increasing confidence in integrating autonomy not only into transportation services but also into manufacturing and vehicle logistics at scale.